Document is current
Any future updates will be listed below
-
Authors
Renwick, Simone
Furst, Annalee
Knip, Mikael
,
Bode, Lars
Danska, Jayne S.
Allen-Vercoe, Emma
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Juvenile Diabetes Research Foundation Canada (5-SRA-2020-952-A-N, 5-SRA-2020-952-A-N, 5-SRA-2020-952-A-N)
Family Larsson Rosenquist Foundation
Seventh Framework Programme (202063)
Academy of Finland (250114)
Anne and Max Tanenbaum Chair in Molecular Medicine, University of Toronto
Hospital for Sick Children Research Institute
Canada Research Chairs
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 8 January 2025
First Online: 7 February 2025
Declarations
:
: Selected fecal samples from the DIABIMMUNE sample database were shipped to the Allen-Vercoe lab following secondary site approval for culture and analysis by the University of Guelph Research Ethics Board, project REB#17-06-006.
: Not applicable.
: E.A.-V. is a co-founder of Nubiyota, a company focused on the human gut microbiome. L.B. is a co-inventor on patent applications related to the use of HMOs in preventing NEC and other inflammatory diseases. S.R., A.F., M.K. and J.D. declare that they have no competing interests.
